Essential Partners
ALNY icon

Essential Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Essential Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$130K Buy
528
+276
+110% +$70.2K 0.06% 349
2026
Q2 		$75.9K Buy
252
+152
+152% +$45.8K 0.04% 493
2026
Q1 		$33.1K Sell
100
-345
-78% -$117K 0.01% 733
2025
Q4 		$177K Sell
445
-791
-64% -$350K 0.05% 341
2025
Q3 		$564K Buy
1,236
+1,174
+1,894% +$478K 0.19% 152
2025
Q2 		$20.2K Buy
+62
New +$17.2K 0.01% 670

Other funds holding ALNY

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Portman Square Capital
Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return
Fideuram - Intesa Sanpaolo Private Banking
Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return
PensionDanmark
PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Sumitomo Mitsui DS Asset Management
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Essential Partners's ALNY Position: Q3 2026 in Review

Essential Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 110% in Q3 2026, buying an estimated $70.2K and bringing the position to 528 shares worth $130K. The position accounts for 0.06% of the portfolio, ranked #349.

Essential Partners first reported a position in ALNY in Q2 2025 and has held it in 6 quarters since. The position peaked at $564K in Q3 2025. 112 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Essential Partners held 528 shares of Alnylam Pharmaceuticals worth $130K as of Q3 2026.
  • Essential Partners bought 276 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $70.2K.
  • Alnylam Pharmaceuticals made up 0.06% of Essential Partners's portfolio in Q3 2026, its #349 holding.
  • Essential Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Alnylam Pharmaceuticals position peaked at $564K in Q3 2025.
  • 112 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.